Dr. Matthias Löhr - Professor of Gastroenterology & Hepatology, Karolinska Institute, Stockholm Sweden

Dr. Matthias Löhr

Dr. Matthias Löhr is Chairman of the Scientific Advisory Board. Dr. Löhr served as Principal Investigator for the Phase 1/2 and Phase 2 clinical trials of PharmaCyte Biotech’s pancreatic cancer treatment that were completed in the early 2000s. Not only is he familiar with the Cell-in-a-Box® live cell encapsulation technology that forms the core of PharmaCyte Biotech’s pancreatic cancer treatment, he has actually administered PharmaCyte Biotech’s treatment (the combination of Cell-in-a-Box® capsules with low doses of the well-known anticancer drug ifosfamide) in clinical trials in patients with advanced, inoperable pancreatic cancer. Dr. Löhr is also serving as a consultant to PharmaCyte Biotech in connection with its development of treatments for pancreatic cancer and diabetes based on the Cell-in-a-Box® technology. Dr. Löhr has expertise in the treatment of both diseases in addition to thoroughly understanding the Cell-in-a-Box® technology and its use in a clinical setting.

Dr. Löhr is Professor of gastroenterology and hepatology at the famed Karolinska Institute in Stockholm, Sweden. He has also served as Professor of Molecular Gastroenterology at the University of Heidelberg and Head of a division at the German Cancer Research Center. Dr. Löhr has also worked as a translational scientist and Principal Investigator in clinical studies in gastrointestinal oncology for many years and has completed a postdoctoral fellowship at the Scripps Clinic & Research Foundation in La Jolla, California. Following receipt of his medical degree, Dr. Löhr served a residency in pathology and a residency in internal medicine and gastroenterology in Erlangen and Rostock in Germany, where he was also an Assistant Professor. Dr. Löhr holds a Ph.D. and an M.D. from the Karolinska University Hospital, Stockholm, Sweden. In addition, Dr. Löhr is a Member of Clinical Cooperation Unit of Molecular Gastroenterology at the German Cancer Research Centre, Heidelberg, Germany.

Dr. Manuel Hidalgo - Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital

Dr. Manuel Hidalgo

In his role at the prestigious Beth Israel Deaconess Medical Center (BIDMC), Dr. Manuel Hidalgo oversees all BIDMC’s clinical cancer programs. Dr. Hidalgo’s groundbreaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer.

The BIDMC’s Cancer Center consists of multiple disciplines including medical oncology, surgical oncology, radiation oncology, radiology and pathology. Twenty-one specialty patient-care programs focus on, among others, pancreatic cancer, breast cancer, prostate cancer and biologic therapy. The Cancer Center, with 160 faculty members and more than $70 million in annual research support, is also home to the Cancer Clinical Trials Office, where hundreds of clinical trials provide patients with access to promising new therapies.

BIDMC is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and The Jackson Laboratory.

Dr. Hidalgo formerly served as the Director of the Clinical Research Program and Vice Director of Translational Research at the Spanish National Cancer Center. From 2011 to 2009, Dr. Hidalgo was Co-Director of both the program for Drug Development and Gastrointestinal Oncology at John Hopkins university in Baltimore, Maryland.

Dr. Hidalgo received his M.D. degree from the University of Navarra in Pamplona and his Ph.D. degree from the University of Autonoma in Madrid, Spain. Dr. Hidalgo completed his training in drug development at the University of Texas Health Science Center in San Antonio, Texas, where he worked closely with Dr. Daniel D. Von Hoff as an Assistant Professor of Medicine.

Dr. Hidalgo currently holds faculty positions at University CEU San Pablo and Johns Hopkins University.

Dr. Hidalgo has been an invited participate or speaker at almost 200 meetings or symposia and co-authored more than 175 scientific articles, 47 review articles, 9 editorials, commentaries and letters to the editors of scientific publications and 8 book chapters. He is currently a reviewer or editor for several major scientific publications and has been or is a member of several international cancer-related organizations. Dr. Hidalgo has received funding from major scientific organizations that include the National Institute of Health, the National Cancer Institute, the American Society of Clinical oncology (ASCO) and the American Association for Cancer Research (AARC). Dr. Hidalgo was the recipient of a Clinical Research Fellowship from the AACR and a Career Development Award from ASCO for his work on epidermal growth inhibitors such as Tarceva®.

Dr Hidalgo’s primary focus now is on the development of novel therapies for pancreatic cancer.

Prof. Dr. Hans-Peter Hammes – Professor of Internal Medicine and Endocrinology, Faculty of Clinical Medicine Mannheim of Heidelberg University and Section Leader for Endocrinology and Diabetology, Mannheim, Germany


Prof. Hans-Peter Hammes, M.D., is internationally recognized as a preeminent figure in the treatment of diabetes and its complications. As evidence of his standing in the area of diabetes, Dr. Hammes was recipient of the prestigious Camillo Golgi Prize awarded by European Association for the Study of Diabetes at that organization’s 2015 annual meeting. Dr. Hammes graduated from the Medical Faculty Münster (Westfälische Wilhelms-Universität, Münster, Germany) and did his medical training at the 3rd and 1st Medical Department at the University Medical Center in Giessen, Germany. After specializing in endocrinology, diabetology and habilitation, Dr. Hammes was appointed Section Head of Endocrinology at the 5th Medical Department, University Medical Center Mannheim, University of Heidelberg, Germany, a position that he currently holds.

Dr. Hammes was trained in diabetes by the one of the world’s most recognized authorities on the treatment of diabetes, Prof. Konrad Federlin, at the University of Giessen, Germany. Dr. Hames‘ research is particularly focused on the microvascular complications that occur with diabetes, in particular the role of glycemia (blood glucose) and other reactive intermediates in the pathogenesis of retinopathy (damage to the retina of the eye that can result in blindness) that can be a consequence of diabetes. As a consequence of these efforts, he has characterized and refined animal models of diabetic microvascular damage and has examined the possible use of drugs to to reduce such damage. His work in this area extends to his collaborating in clinical studies of the effects of such pharmacologic agents on diabetic retinopathy. In addition, Dr. Hammes has long-standing experience in diagnosis and treatment of the complications of obesity, the risk factors associated with the development of diabetes and overt diabetes itself. He has co-authored more than 200 publications on his work. Dr. Hammes has served as a member of the German guideline committee on diabetic retinopathy and maculopathy (damage to the macula of the eye), and, together with collegues from the Universities of Heidelberg and Groningen, he established an international research training platform to deal with microvascular complications that accompany diabetes. In addition to his appointment to PharmaCyte‘s Scientific Advisory Board, Dr. Hammes is also a consultant to the PharmaCyte Biotech and is a member of its international Diabetes Consortium.

Dr. Brian Salmons - Chief Executive Officer and President of Austrianova Pte. Ltd. and Co-Developer of Cell-in-a-Box®


Dr. Brian Salmons received his Ph.D. in London and after research positions in the U.S.A., Switzerland and at the Ludwig Maximilian University, Munich, Germany, he became the Scientific Director of the European biotech/vaccine company, Bavarian Nordic, and was involved in taking the company to IPO. During this time, Dr. Salmons co-invented the “Cell-in-a-Box®” live-cell encapsulation technology that was shown to be safe and efficacious in a Phase I/II clinical trial published in The Lancet. In 2002, he co-founded the Biotech company, Austrianova, originally a spin out of the Veterinary Medicine University in Vienna and was instrumental in obtaining orphan drug status from the European Medicines Agency for its lead cell encapsulation product to treat pancreatic cancer. In 2007, Dr Salmons co-founded and became the CEO of Austrianova Singapore Pte Ltd, an independent company established in Singapore to further develop the encapsulation technology as products for a variety of indications such as various forms of cancer, diabetes, neurodegenerative, cardiovascular and infectious diseases. Dr Salmons is the author or co-author of over 120 peer reviewed scientific articles and inventor of 8 patent families.

Dr. Mark L. Rabe - Chief Executive Officer of Rabe Medical Solutions

dr mark l rabe

Dr. Mark L. Rabe is an integrative medicine specialist and leading figure in the evolving field of cannabinoid medicine. Dr. Rabe earned his medical degree at Northwestern University Medical School. His San Diego medical practice offers natural health care services to support patients as they seek to attain optimal health and manage chronic medical conditions. He is also the Chief Executive Officer of Rabe Medical Solutions, LLC, a company that offers consulting, education and software services to health care practitioners.

Previously, Dr. Rabe served as Chief Medical Officer of California’s largest network of physician-owned integrative care centers. There he hired and trained medical personnel, organized public educational symposia and media outreach, conducted research and supervised the recommendation of natural treatment options to over 100,000 patients in 20 medical clinics across California. Dr. Rabe graduated summa cum laude with a degree in biochemistry from Benedictine University, where he performed research in the area of cancer drug synthesis.

David A. Judd – Cellular Biologist Grand Island Biotechnology Company

David A. Judd

David A. Judd is a graduate of the Biotechnology program at Rochester Institute of Technology, the first Biotechnology program in the United States. He has over 30-years of experience in cell culture and biochemistry in research and in a cGMP environment. Mr. Judd has extensive experience in research and development of cell culture medium and in the growth of human cells, both in the upstream and downstream processes.

Mr. Judd is currently employed by the Grand Island Biotechnology Company (Gibco) and is involved in research, process development and cGMP production of biotechnology and cell therapy processes. He is also involved in regulatory guidance, failure investigations, including root cause analysis, and product investigations and resolutions. Mr. Judd has been employed by Gibco (now owned by ThermoFischer Scientific) for 29 years and is a co-inventor on 5 patents involving cell culture materials.